233846 Department of Medicine, University of Toronto, ON, Canada.
210484 Lynde Institute for Dermatology, Markham, ON, Canada.
J Cutan Med Surg. 2020 May/Jun;24(3):273-277. doi: 10.1177/1203475420903682. Epub 2020 Jan 31.
Psoriasis is a chronic, inflammatory disease with a varying degree of clinical presentations. Managing psoriasis has always been arduous due to its chronicity and its propensity to relapse. Prior to the development of targeted biologic therapies, there were few effective treatments for psoriasis. Ancient psoriasis therapies included pinetar, plant extracts, psychotherapy, arsenic, and ammoniated mercury. In the 19th century, chrysarobin was developed. Then, in the early half of the 20th century, anthralin and coal tar were in widespread use. In the latter half of the 20th century, treatments were limited to topical first-line therapies, systemic drugs, and phototherapy. However, as the treatment of psoriasis has undergone a revolutionary change with the development of novel biologic therapies, patients with moderate to severe psoriasis have been able to avail therapies with high efficacy and durability along with an acceptable safety profile. This article is a brief historical review of the management of psoriasis prior to the inception of biologics and with the development of novel biologic therapies.
银屑病是一种慢性炎症性疾病，临床表现程度不一。由于其慢性和易复发的特点，银屑病的治疗一直很困难。在靶向生物疗法发展之前，银屑病的有效治疗方法很少。古代银屑病的治疗方法包括松焦油、植物提取物、心理疗法、砷和氨化汞。19 世纪，开发了糠馏油。然后，在 20 世纪上半叶，蒽林和煤焦油被广泛使用。20 世纪下半叶，治疗方法仅限于局部一线治疗、全身药物和光疗。然而，随着新型生物疗法的发展，银屑病的治疗发生了革命性的变化，中重度银屑病患者能够获得高效、持久且安全性可接受的治疗方法。本文简要回顾了生物制剂问世前和新型生物制剂发展过程中银屑病的治疗情况。
